These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 35289740)
1. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740 [No Abstract] [Full Text] [Related]
2. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa. Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130 [TBL] [Abstract][Full Text] [Related]
3. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912 [TBL] [Abstract][Full Text] [Related]
6. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Langton Hewer SC; Smyth AR Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937 [TBL] [Abstract][Full Text] [Related]
7. Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa. Cogen JD; Onchiri FM; Hamblett NM; Gibson RL; Morgan WJ; Rosenfeld M Clin Infect Dis; 2021 Sep; 73(6):987-993. PubMed ID: 33693586 [TBL] [Abstract][Full Text] [Related]
9. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412 [No Abstract] [Full Text] [Related]
10. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723 [No Abstract] [Full Text] [Related]
11. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564 [No Abstract] [Full Text] [Related]
12. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109 [TBL] [Abstract][Full Text] [Related]
13. Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis. Mayer-Hamblett N; Kloster M; Rosenfeld M; Gibson RL; Retsch-Bogart GZ; Emerson J; Thompson V; Ramsey BW Clin Infect Dis; 2015 Sep; 61(5):707-15. PubMed ID: 25972024 [TBL] [Abstract][Full Text] [Related]
14. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT. Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975 [TBL] [Abstract][Full Text] [Related]
16. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Smith S; Waters V; Jahnke N; Ratjen F Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436 [TBL] [Abstract][Full Text] [Related]
17. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response. Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462 [TBL] [Abstract][Full Text] [Related]
18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972 [TBL] [Abstract][Full Text] [Related]
19. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis. Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742 [TBL] [Abstract][Full Text] [Related]
20. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447 [No Abstract] [Full Text] [Related] [Next] [New Search]